Clemastine in Cardiovascular Surgery

NCT ID: NCT03826004

Last Updated: 2020-01-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-02-20

Study Completion Date

2020-01-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this study, a prospective, randomized, double-blind pilot trial designed to evaluate the effect of histamine H1 receptor antagonist clemastine on perioperative anaphylaxis in cardiovascular surgery with cardiopulmonary bypass, especially for the efficacy and safety on reducing heparin and protamine associated anaphylaxis.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In this study, a prospective, randomized, double-blind pilot trial designed to evaluate the effect of histamine H1 receptor antagonist clemastine on perioperative anaphylaxis in cardiovascular surgery with cardiopulmonary bypass, especially for the efficacy and safety on reducing heparin and protamine associated anaphylaxis.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Efficacy and Safety

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo

Saline solution 2ml before anesthetic induction

Group Type PLACEBO_COMPARATOR

Saline Solution

Intervention Type DRUG

Saline solution 2ml intramuscular injection is administrated into the gluteus maximus muscle

Clemastine

Clemastine fumarate 2mg/2ml before anesthetic induction

Group Type EXPERIMENTAL

Clemastine

Intervention Type DRUG

Clemastine fumarate 2mg/2ml intramuscular injection is administrated into the gluteus maximus muscle

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Clemastine

Clemastine fumarate 2mg/2ml intramuscular injection is administrated into the gluteus maximus muscle

Intervention Type DRUG

Saline Solution

Saline solution 2ml intramuscular injection is administrated into the gluteus maximus muscle

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18-75 years old
* Receiving selective cardiovascular surgery with cardiopulmonary bypass due to coronary, valvular or congenital heart disease
* Written informed consent obtained.

Exclusion Criteria

* Previous history of cardiac surgery
* Allergy to clemastine, antihistamines with similar chemical structure or any excipient (sorbitol, sodium citrate, propylene glycol, ethanol)
* Myasthenia gravis
* Porphyria patients
* Bronchial asthma
* Usage of monoamine oxidase (MAO) inhibitors
* Pregnant or lactating women
* Mentally or legally disabled patients
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Chinese Academy of Medical Sciences, Fuwai Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

SHI Jia

Assoticate Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jia Shi, M.D.

Role: STUDY_CHAIR

Cardiovascular Institute and Fuwai Hospital, CAMS&PUMC

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Cardiovascular Institute and Fuwai Hospital, CAMS&PUMC

Beijing, Beijing Municipality, China

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Clemastine Pilot Study

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.